A new study shows that combining multiple patient-level biomarkers can better predict which cancer patients will respond to immunotherapy, though generalizability remains a challenge.
A new study shows that combining multiple patient-level biomarkers can better predict which cancer patients will respond to immunotherapy, though generalizability remains a challenge.
Remember the “multi-omic” immunotherapy predictor? Huge promises, then validation spat it out. Nothing. This study is the same circus with one new trick: it openly admits generalizability is a problem. Great. A confession isn’t a cure. Still zero use at the bedside. Another biomarker pile, another decade.